๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Late recurrence of stage I malignant melanoma

โœ Scribed by Mordechai Gutman; Joseph M. Klausner; Moshe Inbar; Ron R. Rozin


Publisher
John Wiley and Sons
Year
1989
Tongue
English
Weight
250 KB
Volume
42
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

โœฆ Synopsis


Although the introduction of well-established risk factors has made the clinical course and prognosis of malignant melanoma disease much more predictable, in a considerable number of patients the disease's course is still not as expected. One group to which this applies are stage I melanoma patients who develop metastatic disease after 10 years or more of a disease-free interval. In our series of 94 such patients, 6 developed late relapse of their disease. The subsequent survival of these patients did not relate to any of the primary tumors' characteristics, but to the pattern of the late recurrence. Four patients with visceral metastases were dead within 1 to 5 years following relapse, one patient with lymph node involvement is alive with metastases, and another patient with skin metastases has no signs of disease following surgcry and immunotherapy.

Our conclusion is that malignant melanoma patients should be placed under close follow-up for the rest of their lives.


๐Ÿ“œ SIMILAR VOLUMES


Tumour thickness and the site and time o
โœ O. W. Milton; H. M. Shaw; G. A. Farago; W. H. McCarthy ๐Ÿ“‚ Article ๐Ÿ“… 1980 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 365 KB ๐Ÿ‘ 2 views

## Summary A study was made of 326 patients first treated for clinical stage I cutaneous malignant melanoma by a wide excision (with or without split-skin graft) but no nodal dissection and who subsequently developed recurrence of their disease. Thick lesions recurred far more frequently than very

Changes in survival with clinical stage
โœ C. P. Karakousis; Dr. S. Kachrimanidis; U. Rao; L. J. Emrich ๐Ÿ“‚ Article ๐Ÿ“… 1987 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 363 KB

Inclusion of patients referred to our cancer center following recurrence, by retracing the history and characteristics of these patients back to when they were in stage I, produced a bias that lowered the estimated diseasefree survival rates. However, taking into consideration only patients referred